Eli Lilly - 52 Year Stock Price History | LLY

Historical daily share price chart and data for Eli Lilly since 1972 adjusted for splits and dividends. The latest closing stock price for Eli Lilly as of May 29, 2024 is 811.53.
  • The all-time high Eli Lilly stock closing price was 811.53 on May 29, 2024.
  • The Eli Lilly 52-week high stock price is 820.61, which is 1.1% above the current share price.
  • The Eli Lilly 52-week low stock price is 428.13, which is 47.2% below the current share price.
  • The average Eli Lilly stock price for the last 52 weeks is 617.10.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Eli Lilly Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 732.2974 590.2103 811.5300 590.2103 811.5300 39.69%
2023 461.3519 360.2197 615.9104 307.5669 580.9614 60.91%
2022 301.7896 264.5967 369.8621 229.4834 361.0586 34.24%
2021 217.3673 158.7518 271.7148 157.6199 268.9689 66.08%
2020 141.3737 124.3072 165.5911 112.5180 161.9556 31.06%
2019 108.7742 106.2337 124.5141 99.8287 123.5739 15.48%
2018 85.7035 76.3911 109.7107 66.9460 107.0105 40.45%
2017 73.2569 65.5839 79.2869 65.5663 76.1926 17.83%
2016 66.3148 70.9551 72.5491 57.9969 64.6608 -10.37%
2015 66.6866 58.4387 76.5646 57.4703 72.1452 25.37%
2014 50.6895 40.9589 60.7492 40.9589 57.5462 39.75%
2013 41.7690 38.5457 45.8288 38.1028 41.1769 7.24%
2012 33.2273 31.0781 41.4624 28.9781 38.3978 24.27%
2011 26.7143 24.6624 31.0410 24.0334 30.8997 25.15%
2010 24.1271 23.8801 26.4483 22.1156 24.6906 3.71%
2009 22.2775 25.5822 25.5822 17.5529 23.8067 -6.25%
2008 28.0326 31.7296 34.5252 18.8603 25.3930 -21.23%
2007 33.0070 30.6000 35.7444 29.6405 32.2368 5.65%
2006 31.7990 32.6097 33.8633 29.0915 30.5121 -5.16%
2005 30.8521 31.1051 33.8237 28.0814 32.1719 2.52%
2004 36.0090 38.5539 41.4668 27.7154 31.3816 -17.55%
2003 34.0325 35.0915 39.9880 28.6101 38.0614 13.14%
2002 34.0154 40.7832 42.0917 25.2379 33.6399 -17.56%
2001 41.1475 46.8907 46.8907 37.3302 40.8040 -14.44%
2000 40.0887 33.1282 55.2488 27.6557 47.6902 41.92%
1999 37.9893 42.9217 48.7593 30.9828 33.6032 -24.25%
1998 35.4496 34.0248 45.3572 28.8358 44.3591 29.08%
1997 25.7599 17.5789 34.5184 17.5789 34.3654 94.15%
1996 15.1416 13.1384 19.2156 11.7434 17.7001 32.64%
1995 9.3860 7.4806 13.4041 7.2088 13.3448 77.39%
1994 6.3343 6.5077 7.5230 5.2621 7.5230 15.60%
1993 5.5339 6.4164 6.6436 4.7292 6.5077 2.47%
1992 7.0351 8.5951 8.8220 6.1004 6.3506 -24.89%
1991 7.7622 7.2138 8.5951 6.8420 8.4554 16.41%
1990 7.0271 6.6301 8.8003 5.7627 7.2634 9.95%
1989 5.4274 4.0296 6.6059 4.0296 6.6059 64.17%
1988 3.8523 3.6471 4.2837 3.2469 4.0239 12.81%
1987 4.0001 3.3732 4.7529 2.8167 3.5670 5.75%
1986 3.1711 2.4930 3.7480 2.3112 3.3732 33.19%
1985 1.9266 1.4737 2.5327 1.4708 2.5327 68.94%
1984 1.3831 1.3515 1.5192 1.2266 1.4992 14.03%
1983 1.4231 1.3034 1.5532 1.2891 1.3147 0.66%
1982 1.2926 1.2664 1.4765 1.0562 1.3061 2.68%
1981 1.3249 1.4310 1.5503 1.0590 1.2720 -11.98%
1980 1.2105 1.3175 1.4451 1.0476 1.4451 6.70%
1979 1.2563 1.0903 1.4424 1.0817 1.3543 24.87%
1978 1.0221 0.8575 1.2209 0.8348 1.0846 26.06%
1977 0.8814 1.0703 1.0703 0.7469 0.8604 -20.46%
1976 1.1716 1.1612 1.3629 0.9908 1.0817 -7.74%
1975 1.4936 1.5246 1.7972 1.1557 1.1725 -24.09%
1974 1.5753 1.6668 1.8654 1.2777 1.5446 -8.11%
1973 1.8538 1.7972 2.0811 1.5928 1.6809 -7.06%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $767.795B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $601.688B 46.23
Johnson & Johnson (JNJ) United States $347.476B 13.80
Merck (MRK) United States $319.362B 58.11
AbbVie (ABBV) United States $274.310B 14.17
AstraZeneca (AZN) United Kingdom $237.558B 20.65
Novartis AG (NVS) Switzerland $203.746B 14.45
Pfizer (PFE) United States $160.365B 19.93
Sanofi (SNY) $121.278B 11.44
Innoviva (INVA) United States $0.970B 6.82